2007
DOI: 10.1016/j.yexcr.2007.06.022
|View full text |Cite
|
Sign up to set email alerts
|

Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context

Abstract: Hsp90 inhibitors are currently in clinical trials for cancer therapy based on their ability to promote proteasomal degradation of oncogenic protein kinases and nuclear receptors. Results from recent studies suggest that cancer cells are more sensitive to these inhibitors than cells from healthy tissues. We analyzed an immortalized cell line Ba/F3, for sensitivity to the Hsp90 inhibitor geldanamycin in the absence and presence of the oncogenic tyrosine fusion kinase NPM-ALK expressed from a retroviral vector. O… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
18
0

Year Published

2008
2008
2020
2020

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 21 publications
(21 citation statements)
references
References 28 publications
3
18
0
Order By: Relevance
“…In addition, total-Akt expression was reduced by Hsp90 blockade in HepG2 and Hep3B cells, but not in Huh-7 cells, a variable effect reported previously. 25 Otherwise, the effects of this dual-inhibition in terms of pathway inhibition were similar to 17-DMAG treatment alone (Fig. 1C).…”
Section: Impact Of Combining Hsp90 and Mtormentioning
confidence: 65%
“…In addition, total-Akt expression was reduced by Hsp90 blockade in HepG2 and Hep3B cells, but not in Huh-7 cells, a variable effect reported previously. 25 Otherwise, the effects of this dual-inhibition in terms of pathway inhibition were similar to 17-DMAG treatment alone (Fig. 1C).…”
Section: Impact Of Combining Hsp90 and Mtormentioning
confidence: 65%
“…Differential TrkAI and TrkAIII transfectant sensitivity to GA resulted in GA selection of TrkAIII transfectants from co-culture with TrkAI transfectants, confirming TrkAIII negative impact on GA-induced NB cell eradication and adding TrkAIII to other oncogenes, including ERGFR, which decrease tumour cell GA sensitivity (Theodoraki et al, 2007;Puyo et al, 2008). This, combined with TrkAIII re-phosphorylation after GA removal, provides a potential mechanism for post GA therapeutic relapse.…”
Section: Hsp90 Interacts With Trkai and Trkaiii In Neuroblastoma Cellsmentioning
confidence: 78%
“…In the oncogenic tyrosine kinase fusion nucleophosmin-anaplastic lymphoma receptor tyrosine kinase (NPM-ALK) model, downstream kinase AKT displayed increased activity as well as an increased dependency on HSP90 for its stability (8). This model suggests that attributes of AKT associated with its activity are recognized by the chaperone complex and is consistent with previous and striking observations that numerous cancer-promoting kinases, whether activated through mutation, aberrant upstream activation, or gene upregulation, are more dependent on HSP90 activities than their counterparts in normal cells (9).…”
mentioning
confidence: 99%